Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

   Terminated · Phase 2 · Breast Cancer Metastatic

   NCT04659603 · Sanofi US Services Inc. · 1 U.S. investigator

   $25,730research payments

2. Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

   Completed · Phase 1 · Virus, Zika

   NCT03343626 · Takeda Pharmaceuticals U.S.A., Inc. · 2 U.S. investigators

   $25,500research payments

3. Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

   Active, not recruiting · Not applicable · Partial-thickness Burn

   NCT04839523 · Molnlycke Health Care Ab · 5 U.S. investigators

   $25,388research payments

4. BAROSTIM NEO Hypertension Pivotal Trial

   Completed · Not applicable · Uncontrolled Hypertension

   NCT01679132 · Cvrx, Inc. · 5 U.S. investigators

   $25,357research payments

5. Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

   Completed · Phase 2 · Acute Bacterial Skin and Skin Structure Infection

   NCT05599295 · Melinta Therapeutics, LLC · 2 U.S. investigators

   $25,344research payments

6. An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

   Recruiting · Phase 2 · Prostate Carcinoma

   NCT06865768 · Blue Earth Diagnostics · 1 U.S. investigator

   $25,329research payments

7. The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

   Completed · Phase 4 · Asthma

   NCT04400318 · Genzyme Corporation · 0 U.S. investigators

   $25,250research payments

8. Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

   Enrolling by invitation · Phase 3 · Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

   NCT02796937 · Grifols Therapeutics LLC · 3 U.S. investigators

   $25,097research payments

9. A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

   Recruiting · Phase 1, Phase 2 · Anemia, Sickle Cell

   NCT06481306 · E.r. Squibb & Sons, L.l.c. · 5 U.S. investigators

   $25,050research payments

10. A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

    Recruiting · Phase 4 · Hemophilia A

    NCT06145373 · Genzyme Corporation · 1 U.S. investigator

    $24,955research payments

11. A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

    Completed · Phase 2 · Nonalcoholic Steatohepatitis

    NCT04166773 · Eli Lilly and Company · 2 U.S. investigators

    $24,924research payments

12. A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

    Active, not recruiting · Phase 1 · Breast Neoplasms

    NCT02057133 · Eli Lilly and Company · 1 U.S. investigator

    $24,813research payments

13. An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

    Terminated · Phase 1 · Advanced or Metastatic MTAP-deleted Solid Tumors

    NCT06568614 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $24,750research payments

14. Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation

    Completed · Not applicable · Obstructive Sleep Apnea

    NCT06560411 · Breas Medical, Inc. · 5 U.S. investigators

    $24,726research payments

15. A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

    Completed · Phase 2 · Pulmonary Arterial Hypertension

    NCT04712669 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

    $24,698research payments

16. AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

    Completed · Phase 1, Phase 2 · Advanced Retinitis Pigmentosa

    NCT02556736 · AbbVie Inc. · 1 U.S. investigator

    $24,644research payments

17. Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

    Completed · Phase 1 · Leukemia, Lymphocytic, Chronic, B-Cell

    NCT05024045 · Eli Lilly and Company · 2 U.S. investigators

    $24,521research payments

18. Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

    Completed · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT03930732 · Genzyme Corporation · 1 U.S. investigator

    $24,504research payments

19. A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

    Completed · Phase 3 · Beta-Thalassemia

    NCT03207009 · Genetix Biotherapeutics Inc · 1 U.S. investigator

    $24,220research payments

20. High Dose Risankizumab for Psoriasis

    Completed · Phase 2 · Psoriasis

    NCT05283135 · AbbVie Inc. · 2 U.S. investigators

    $23,550research payments

21. A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

    Completed · Phase 3 · Cerebral Adrenoleukodystrophy (CALD)

    NCT03852498 · Genetix Biotherapeutics Inc · 1 U.S. investigator

    $23,527research payments

22. To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

    Not yet recruiting · Phase 3 · Amyloidosis in Transthyretin (TTR)

    NCT07116473 · Eidos Therapeutics, Inc. · 1 U.S. investigator

    $23,525research payments

23. Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain

    Recruiting · Amputation

    NCT06908538 · Atricure, Inc. · 1 U.S. investigator

    $23,390research payments

24. JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance

    Completed · Phase 3 · Neck Lines

    NCT05316233 · AbbVie Inc. · 12 U.S. investigators

    $23,308research payments

25. Evaluating the SUBLOCADE Treatment Exit Strategy

    Completed · Opioid Use Disorder

    NCT05878210 · Indivior Inc. · 3 U.S. investigators

    $22,573research payments

26. Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

    Completed · Phase 4 · Dry Eye Disease

    NCT05514041 · Oyster Point Pharma, Inc. · 1 U.S. investigator

    $22,500research payments

27. A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

    Completed · Phase 2 · Systemic Lupus Erythematosus (SLE)

    NCT04451772 · AbbVie Inc. · 2 U.S. investigators

    $22,422research payments

28. Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

    Active, not recruiting · Phase 2 · Recurrent Glioma

    NCT05859334 · Caris Mpi, Inc. · 1 U.S. investigator

    $22,400research payments

29. Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

    Completed · Phase 3 · Hematopoietic Stem Cells

    NCT03657160 · Takeda Pharmaceuticals U.S.A., Inc. · 2 U.S. investigators

    $22,071research payments

30. A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

    Enrolling by invitation · Phase 3 · Irritable Bowel Syndrome

    NCT04880876 · AbbVie Inc. · 6 U.S. investigators

    $22,067research payments

31. A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

    Completed · Phase 3 · Acute Myeloid Leukemia (AML)

    NCT04102020 · AbbVie Inc. · 6 U.S. investigators

    $22,052research payments

32. DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

    Active, not recruiting · Not applicable · Pulmonary Arterial Hypertension

    NCT01321073 · United Therapeutics Corporation · 0 U.S. investigators

    $22,017research payments

33. A Study of LY3437943 in Participants With Type 2 Diabetes

    Completed · Phase 2 · Type 2 Diabetes

    NCT04867785 · Eli Lilly and Company · 2 U.S. investigators

    $21,822research payments

34. A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Terminated · Phase 2 · Neoplasms, Ovarian

    NCT05613088 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $21,750research payments

35. Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

    Completed · Phase 1 · Gram-positive Bacterial Infections

    NCT02134301 · Melinta Therapeutics, LLC · 2 U.S. investigators

    $21,670research payments

36. Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

    Completed · Phase 2 · Leigh Syndrome

    NCT02352896 · Ptc Therapeutics, Inc. · 1 U.S. investigator

    $21,515research payments

37. Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

    Completed · Phase 3 · Eosinophilic Esophagitis

    NCT04991935 · E.r. Squibb & Sons, L.l.c. · 0 U.S. investigators

    $21,321research payments

38. Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

    Completed · Phase 2 · Irritable Bowel Syndrome

    NCT03339128 · AbbVie Inc. · 16 U.S. investigators

    $21,293research payments

39. A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

    Completed · Phase 2 · Sphingomyelin Lipidosis

    NCT02004704 · Genzyme Corporation · 1 U.S. investigator

    $21,211research payments

40. Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

    Completed · Phase 2 · Multiple Myeloma

    NCT01946477 · Celgene Corporation · 2 U.S. investigators

    $21,197research payments

41. A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

    Completed · Phase 3 · Spondyloarthritis

    NCT04169373 · AbbVie Inc. · 2 U.S. investigators

    $21,170research payments

42. A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

    Completed · Phase 3 · Generalized Myasthenia Gravis

    NCT05681715 · UCB SA · 1 U.S. investigator

    $21,117research payments

43. Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

    Completed · Phase 1 · RSV Infection

    NCT06583031 · Sanofi Pasteur Inc. · 0 U.S. investigators

    $21,000research payments

44. Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

    Completed · Phase 1 · Respiratory Syncytial Virus Infection

    NCT06604767 · Sanofi Pasteur Inc. · 0 U.S. investigators

    $21,000research payments

45. A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

    Completed · Phase 3 · Generalized Myasthenia Gravis

    NCT04650854 · UCB SA · 3 U.S. investigators

    $20,978research payments

46. Stone and Laser Therapies Post-Market Study (SALT)

    Active, not recruiting · Benign Prostate Hypertrophy(BPH)

    NCT06982235 · Boston Scientific Corporation · 2 U.S. investigators

    $20,906research payments

47. Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

    Completed · Phase 4 · Dermatitis Atopic

    NCT04823130 · Genzyme Corporation · 1 U.S. investigator

    $20,830research payments

48. Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

    Active, not recruiting · Phase 1, Phase 2 · Atypical Teratoid Rhabdoid Tumor

    NCT05407441 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $20,829research payments

49. Philps FAST2022 picoSAT Pulse Oximetry Desaturation Study

    Completed · SpO2 (Peripheral Oxygen Saturation) Measurement Validation

    NCT05683366 · Philips North America LLC · 1 U.S. investigator

    $20,790research payments

50. Pilot Study of Acute Stroke Using the Brainpulse™

    Completed · Stroke, Acute

    NCT03235271 · Jan Medical Inc. · 1 U.S. investigator

    $20,726research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.